Bank stocks have rebounded in recent months as strong results from lenders' retail businesses helped drive firms to record profits.Financeread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
Johnson & Johnson reports second-quarter earnings Tuesday before market open.Health and Scienceread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Analysts polled by Refinitiv are expecting earnings of $4.89 per share and revenue of $8.828 billion when Goldman Sachs reports second-quarter earnings Tuesday.Financeread more
Early Facebook investor and Trump supporter Peter Thiel weighed in on the Democrats taking on the president in 2020, saying he was "most scared' by Elizabeth Warren.Politicsread more
Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Treasury Secretary Steven Mnuchin is raising red flags ahead of Facebook's proposed cryptocurrency launch.Marketsread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
Beto O'Rourke's campaign for the 2020 election raised just $3.6 million in the second quarter of this year, putting him in the lower tier of candidates who have struggled to...2020 Electionsread more
The FDA granted accelerated approval for Sarepta's eteplirsen treatment for Duchenne muscular dystrophy in September 2016. The company revealed on Tuesday it generated $5.4 million of sales in the December 2016 quarter from the drug.
Sarepta shares were up more than 20 percent midafternoon Tuesday and have risen about 38 percent year to date.
On the eteplirsen drug's start: "The launch is going very well," he said. "There's a lot of enthusiasm for the therapy from the patients and also from the physicians. Today we talked about there were over 100 physicians who sent in some of the early prescription forms. And just overall we've been very, very pleased about the reception."
Kaye also commented on reimbursement trends, drug pricing and the company's future pipeline.
To watch the interview in its entirety, you must be a CNBC PRO subscriber.